MedWatch

Synact ready for phase II with arthritis candidate: "An important milestone for the company"

After finishing phase I trials, Danish biotech company Synact has applied for the authorities' permission to initiate a phase II study with the company's lead candidate against rheumatoid arthritis. According to the CEO, the company has various financing opportunities.

Foto: Synact Pharma PR

Læs artiklen gratis

Registrer med din E-mail.
Det kræver intet kreditkort.

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier